Drug Patents owned by Bausch And Lomb

1. Drug name - BESIVANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8481526 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals
Jan, 2031

(8 years from now)

CN102369189B BAUSCH AND LOMB Fluoroquinolone Carboxylic Acid Molecular Crystals
Mar, 2030

(7 years from now)

CN102369189A BAUSCH AND LOMB Fluoroquinolone Carboxylic Acid Molecule Crystal
Mar, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8937062 BAUSCH AND LOMB Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria Nov, 2029

(7 years from now)

US8604020 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals Mar, 2030

(7 years from now)

US8415342 BAUSCH AND LOMB Besifloxacin ophthalmic composition for the treatment or control of infection Nov, 2030

(8 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.6% BASE SUSPENSION/DROPS;OPHTHALMIC Prescription

2. Drug name - PROLENSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129431 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Sep, 2025

(2 years from now)

CN100341498C BAUSCH AND LOMB Containing 2-Amino - -3-(4-Bromine-Benzoyl) Phenylacetic Acid Aqueous Liquid Preparation
Jan, 2024

(1 year, 3 months from now)

CN1700913A BAUSCH AND LOMB Containing 2-Amino - -3-(4-Bromine-Benzoyl) Phenylacetic Acid Aqueous Liquid Preparation
Jan, 2024

(1 year, 3 months from now)

EP1586316A1 BAUSCH AND LOMB Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid
Jan, 2024

(1 year, 3 months from now)

EP1586316A4 BAUSCH AND LOMB Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid
Jan, 2024

(1 year, 3 months from now)

EP1586316B1 BAUSCH AND LOMB Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid
Jan, 2024

(1 year, 3 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144609 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid Jan, 2024

(1 year, 3 months from now)

US8754131 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid Jan, 2024

(1 year, 3 months from now)

US8927606 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid Jan, 2024

(1 year, 3 months from now)

US9561277 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid Jan, 2024

(1 year, 3 months from now)

US8669290 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid Jan, 2024

(1 year, 3 months from now)

US8871813 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid Jan, 2024

(1 year, 3 months from now)

US10085958 BAUSCH AND LOMB Bromfenac bioavailability Nov, 2032

(10 years from now)

US9517220 BAUSCH AND LOMB Bromfenac bioavailability Nov, 2033

(11 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Treatment: Method of treating ocular inflammation; method of treating ocular inflammation; method of treatment to alleviate inflammation of the eye; Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.07% ACID SOLUTION/DROPS;OPHTHALMIC Prescription

3. Drug name - VYZULTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7910767 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(2 years from now)

US8058467 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(2 years from now)

US7273946 BAUSCH AND LOMB Prostaglandin derivatives
Oct, 2025

(2 years from now)

CN100469765C BAUSCH AND LOMB Prostaglandin Nitroxide Derivative
Dec, 2024

(2 years from now)

CN1906159A BAUSCH AND LOMB The Prostaglandin Nitroxide Derivative
Dec, 2024

(2 years from now)

IN276779B BAUSCH AND LOMB Prostaglandin Nitrooxyderivatives
Dec, 2024

(2 years from now)

IN200603240P1 BAUSCH AND LOMB Prostaglandin Derivatives
Dec, 2024

(2 years from now)

EP1704141B1 BAUSCH AND LOMB Prostaglandin Nitrooxyderivatives
Dec, 2024

(2 years from now)

EP1704141A1 BAUSCH AND LOMB Prostaglandin Nitrooxyderivatives
Dec, 2024

(2 years from now)

EP3002277B1 BAUSCH AND LOMB Prostaglandin Derivatives
Dec, 2024

(2 years from now)

EP3002277A1 BAUSCH AND LOMB Prostaglandin Derivatives
Dec, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7629345 BAUSCH AND LOMB Prostaglandin derivatives Jan, 2025

(2 years from now)

Drugs and Companies using LATANOPROSTENE BUNOD ingredient

Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.024% SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.